Accessibility Menu
Csl logo

Csl(OTC) CSLLY

Market Cap$41.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+394%
5 Year-56%
1 Year-49%
1 Month+6%
$21.64
-4.71%
-1.07Today
Csl last closing stock price
MetricPriceDate
Last closeUSD 21.642026-07-31
Csl stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.2%USD 20.002026-07-24
1 month+5.56%USD 20.502026-07-01
3 month-3.39%USD 22.402026-05-01
Year to date-23.93%USD 28.452025-12-31
1 year-49.06%USD 42.482025-07-31
3 year-48.29%USD 41.852023-08-01
5 year-56.13%USD 49.332021-07-30
Since inception+394.24%USD 4.382008-11-19

Csl Financials at a Glance

Market Cap

$41.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$30.52B

Net Income (TTM)

$4.18B

EPS (TTM)

$0.72

P/E Ratio

29.99

Dividend

$1.13

Beta (Volatility)

0.70 (Low)

Price

$21.64

Volume

176,686

Open

$21.44

Previous Close

$21.64

Daily Range

$21.27 - $21.97

52-Week Range

$16.01 - $44.77

Estimated Earnings Date

Feb 10, 2026

CSLLY News

cellectis

Why Shares of uniQure Are Dropping Tuesday

James HalleySep 5, 2023
Plasma donation

Who Can Donate Plasma for COVID-19 Patients?

Brian Orelli, PhDJun 14, 2020
Coronavirus patient 2

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy

Brian Orelli, PhDApr 8, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Csl

CSL Limited is a global biopharmaceutical enterprise focused on the research, development, production, marketing, and distribution of a diverse range of biopharmaceutical products. With a significant international presence, CSL operates in major markets including Australia, the United States, Germany, and China, among others.

Products and Services
  • CSL Behring specializes in plasma-derived and recombinant therapies
  • Seqirus focuses on biotherapeutic products, particularly influenza solutions
  • Extensive research into both plasma and non-plasma-based treatments
Growth Outlook
  • Revenue for Q2 2025 reached $8.3 billion, showing strong demand
  • Net income for Q2 2025 was $401.7 million, reflecting operational efficiency
  • Continued investment in R&D, with $601 million allocated in Q2 2025
Financial Highlights
  • Trailing twelve-month revenue of $30.5 billion, indicating robust growth
  • Dividend yield of 3.5%, appealing for income-focused investors
  • Operating income margin of 31.3% in Q2 2025, showcasing profitability
CSL Limited has established itself as a leader in the biopharmaceutical industry, driven by its commitment to innovation and patient care. The company's dual focus on plasma-derived therapies and influenza solutions positions it well for future growth. Recent financial performance highlights a strong revenue trajectory and solid profitability, making it an attractive option for potential investors. The ongoing investment in research and development underscores CSL's dedication to advancing healthcare solutions, further enhancing its market position.
AI Generated • Jul 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29,000

CEO

Paul McKenzie, PhD

Website

www.csl.com.au

Headquarters

Melbourne, VIC 3052, AU

CSLLY Financials

Key Financial Metrics (TTM)

Gross Margin

48.64%

Operating Margin

25.72%

Net Income Margin

9.17%

Return on Equity

7.56%

Return on Capital

9.60%

Return on Assets

3.80%

Earnings Yield

3.33%

Dividend Yield

3.35%

Payout Ratio

1.03%

Stock Overview

Market Cap

$41.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.92B

Volume

176.69K

Avg. Volume

457.66K

Financials (TTM)

Gross Profit

$15.22B

Operating Income

$7.95B

EBITDA

$9.90B

Operating Cash Flow

$6.70B

Capital Expenditure

-$1.33B

Free Cash Flow

$5.37B

Cash & ST Invst.

$1.15B

Total Debt

$12.57B

Csl Performance Analysis

Csl annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 10,456,909,745N/A
20232023-06-30USD 13,114,573,12825.4%
20242024-06-30USD 14,741,889,37912.4%
20252025-06-30USD 15,403,768,6024.5%
Csl sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-19.3%
Q22024-12-3121.7%
Q42025-06-30-11.7%
Q22025-12-3114.4%
Csl annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 1.19N/A
20232023-06-30USD 1.15-3.4%
20242024-06-30USD 1.3718.4%
20252025-06-30USD 1.5412.8%
Csl sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-43.3%
Q22024-12-3178.0%
Q42025-06-30N/A
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$8.30B

-0.7%

Gross Profit

$4.21B

-1.9%

Gross Margin

50.68%

N/A

Market Cap

$41.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.27M

N/A

Employees

32,698

N/A

Net Income

$401.70M

-79.7%

EBITDA

$3.09B

-3.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.15B

+12.8%

Total Debt

$12.57B

+4.1%

Accounts Receivable

$4.13B

+16.3%

Inventory

$6.57B

+18.3%

Long Term Debt

$11.85B

+3.9%

Short Term Debt

$717.00M

-53.9%

Return on Assets

3.80%

N/A

Return on Invested Capital

12.12%

N/A

Free Cash Flow

$1.01B

+163.2%

Operating Cash Flow

$1.30B

+16.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
UCBJYUCB S.A.
$128.52+2.93%
UCBJFUCB S.A.
$269.66+3.88%
GNMSFGenmab A/S
$289.16+0.00%
CHGCFChugai Pharmaceutical Co., Ltd.
$43.18-7.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About CSLLY

What is the current price of Csl?

Csl is trading at $21.64 per share.

What is the 52-week range for Csl?

Over the past 52 weeks, Csl has traded between $16.01 and $44.77.

How much debt does Csl have?

As of the most recent reporting period, Csl reported total debt of $11.50B.

How much cash does Csl have on hand?

Csl reported $2.16B in cash and cash equivalents in its most recent financial results.

What is Csl’s dividend yield?

Csl currently has a dividend yield of 3.35%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services